Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages

Arduino A. Mangoni, Gian Luca Erre

Research output: Contribution to journalEditorial

Abstract

The ongoing coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to national healthcare systems and economies because of its unpredictable progress, the failure to successfully protect vulnerable populations, the paucity of proven therapies pending the development of effective vaccines, and the emerging evidence of long-term sequelae affecting different organs and systems.1–3 Despite these uncertainties, tens of thousands of peer-reviewed papers have been published over the last few months on all aspects of the disease, including the effects of different pharmacological treatments. The rapid understanding of the mechanisms involved in the host interaction and replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for COVID-19, has led to the early identification of specific agents that could be repurposed for the management of the disease.4
Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalTherapeutic Advances in Drug Safety
Volume12
DOIs
Publication statusPublished - 2021

Keywords

  • clinical trials
  • COVID-19
  • drug repurposing
  • evidence
  • machine learning
  • trial hibernation

Fingerprint Dive into the research topics of 'Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages'. Together they form a unique fingerprint.

Cite this